Curriculum Vitae

Mark E. Dato, M.D., Ph.D.
markdato@gmail.com
Updated 1/2023

Education/Professional Experience

1977-1981	B.S. (Biology) Loyola University of the South, New Orleans, LA
1981-1991	Ph.D. (1989, Dept. of Microbiology and Immunology) M.D. (1991)University of Health Sciences, The Chicago Medical School North Chicago, Illinois
1991-1994	Resident in Pediatrics, Children's Hospital Medical Center, Cincinnati , Ohio
1994-1997	Fellow, Pediatric Pulmonology, Children's Hospital Medical Center, Cincinnati, Ohio

Work History

1997- 2007	Adjunct Clinical Instructor – Dept of Pulmonary Medicine, Cincinnati Children's Hospital.
1997-1999	Scientist, Clinical Pharmacology and Pharmacokinetics, Procter& Gamble Pharmaceuticals
2000-2005	Section Head, Early Drug Development, Procter and Gamble Pharmaceuticals
2005-2007	Associate Director, Early Drug Development Procter & Gamble Pharmaceuticals
2007–2008	Director, Global Musculoskeletal Category, Procter & Gamble Pharmaceuticals
2009-2010	Director, Statistics, Data Management, Scientific Writing and Clinical, Procter & Gamble
2010 –2012	Director - Product Safety & Regulatory Affairs Global Beauty Care. Procter & Gamble
2012- 2016	Director, Global Quality and Health Complaints Management, Global Product Stewardship GCO, Corporate Function R&D
2016- 2017	Director, Global Technology, PGT Healthcare, Geneva Switzerland
2017-2019/current	Retired
11/2019 – 8/2022	Chief Scientific/Chief Medical Officer Eikonoklastes Therapeutics, Inc
9/2022 – current	Retired

Boards and Appointments

2018 – 2021 Court Appointed Special Advocate (CASA), Cook County, Chicago

Publications

Dato M. and Kim Y.B. Production and characterization of monoclonal antibodies against porcine natural killer cells. Fed Proc 1986; 45:1117 .

Dato M. and Kim Y.B. Characterization and utilization of a monoclonal antibody inhibiting porcine natural killer cell activity for isolation of natural killer cells. J Immunol 1990; 144:4452-4462.

Dato ME, Wierda W.G. and Kim Y.B. A triggering structure recognized by G7 monoclonal antibody on porcine lymphocytes and granulocytes. Cell Immunol 1992; 140:468-477.

Wierda W.G, Johnson B.D., Dato M.E., Kim Y.B. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. Cell Immunol 1993; 146:270-283.

Wierda W.G., Johnson, B.D., Dato M.E. and Kim Y.B. Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). J Immunol 1993;151:7117-7127.

M. Dato, contributing author. Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices and Cosmetics. Parenteral Drug Association, Technical Report 67, 2014

Abstracts

Dato M. and Kim Y.B. Production and characterization of monoclonal antibodies against porcine natural killer cells. Proc of the 24th Annual Meeting of the Association of Gnotobiotics, No. 11.

Dato M. and Kim Y.B. Characterization and functional analysis of a porcine natural killer inhibitory (PNK-I) monoclonal antibody. FASEB Journal 1988; A460 (Abstract No. 954)

Dato M. and Kim Y.B. Characterization of a monoclonal antibody inhibiting porcine natural killer cell activity (PNK-I). FASEB Journal 1989; 3:A816 (Abstract No. 3429).

Dato M.E, Jones, M.L. and Greenberg, J.M. Cloning and characterization of the promoter region of the murine keratinocyte growth factor (KGF) gene. (FASEB, 1997).

Jones, M.L., M.E. Dato, R. Gendron, H. Wong , J.M. Greenberg. Regulation of KGF/FGF-7 expression in immortalized clonal mouse fetal lung memenchymal cells. (FASEB, 1997).

Guler, Hans-Peter, Ann Acheson, Nancy Stambler, Thomas L. Hunt and Mark Dato. First in human study with AXOKINE: A second generation CNTF with potential as a weight loss drug. ENDO 2000 (Abstract # 850508).

McRobie, CL, Buch, AB, Thompson, GA, Dato, ME, Kelly, SC, Agnew, JR, Skuster, JR, and Mitchell, DY Bisoprolol Pharmacokinetics and Pharmacodynamics in Pediatric Subjects, 6 Months to 6 Years of Age. AAPS Pharmsci. 2000; 2(4)

McRobie, CL, Thompson, GA, Dato, ME, Johnson, TD, Seeck, MJ, Russell, DA, Skuster, JR, and Mitchell, DY. Pharmacokinetics of Ziac® (bisoprolol fumarate/hydrochlorothiazide) and Zebeta® (bisoprolol fumarate) in Children, 6 Through 15 Years of Age. AAPS Pharmsci. 2000; 2(4)

Book Chapters

Wilmott, Robert and M. Dato. 1996. Respiratory Diseases. In *Rudolph's Fundamentals of Pediatrics*, eds. A.M. Rudolph and R.K. Kamei. Appleton and Lange, Stanford, CT. 2nd ed.

Wilmott, Robert, B. Chini and M. Dato. 2000. Respiratory Diseases. In *Rudolph's Fundamentals of Pediatrics*, eds. A.M. Rudolph and R.K. Kamei. Appleton and Lange, Stanford, CT. 3rd ed.